Compare NOA & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOA | SLN |
|---|---|---|
| Founded | 1953 | 1994 |
| Country | Canada | United Kingdom |
| Employees | N/A | 88 |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.9M | 300.9M |
| IPO Year | 2006 | N/A |
| Metric | NOA | SLN |
|---|---|---|
| Price | $13.39 | $10.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 66.0K | ★ 622.1K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.77 | N/A |
| Revenue Next Year | $5.43 | N/A |
| P/E Ratio | $18.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.07 | $4.19 |
| 52 Week High | $17.26 | $11.06 |
| Indicator | NOA | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 64.90 |
| Support Level | $13.27 | $5.87 |
| Resistance Level | $14.85 | $11.06 |
| Average True Range (ATR) | 0.36 | 0.83 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 47.23 | 72.56 |
North American Construction Group Ltd is Canada's heavy civil construction and mining contractor provider. The company has provided services to oil, natural gas, and resource companies. The Company provides a wide range of mining and heavy civil construction services to customer in the resource development and industrial construction sectors within Canada, the United States, and Australia. The Company's reportable segments are Heavy Equipment Canada, Heavy Equipment Australia, and Other. Heavy Equipment Canada and Heavy Equipment Australia include all of aspects of the mining and heavy civil construction services provided within those geographic areas. Other includes mine management contract work in the United States, its external maintenance and rebuild programs.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.